Biogen (NASDAQ:BIIB) reported Q4 2017 earnings this Morning, coming in at $5.26 per share, missing Wall Street’s estimates of $5.44 per Share. Revenue for the quarter came in at $3.31 billion beating analyst estimates of $3.08 billion Recent Insider Trading for Biogen (NASDAQ:BIIB)
- On 12/29/2018 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 1/9/2018 Robert W Pangia, Director, sold 5,832 with an average share price of $329.65 per share and the total transaction amounting to $1,922,518.80.
- On 12/29/2017 Michel Vounatsos, CEO, bought 780 with an average share price of $320.55 per share and the total transaction amounting to $250,029.00.
- On 11/29/2017 Alexander J Denner, Director, bought 30,000 with an average share price of $317.36 per share and the total transaction amounting to $9,520,800.00.
- On 7/25/2017 Susan H Alexander, EVP, sold 4,974 with an average share price of $290.01 per share and the total transaction amounting to $1,442,509.74.
- On 7/19/2017 Susan H Alexander, EVP, sold 7,758 with an average share price of $285.00 per share and the total transaction amounting to $2,211,030.00.
Recent Trading for Biogen (NASDAQ:BIIB) Shares of Biogen closed the previous trading session at 357.09 up +10.59 3.06% with 80514 shares trading hands.